Bi­cy­cle sets terms for $65M IPO; Lil­ly's Cyra­mza wins fifth can­cer ap­proval

→ On­col­o­gy com­pa­ny Bi­cy­cle Ther­a­peu­tics, which has put its faith in syn­thet­ic short pep­tides that it be­lieves can de­liv­er a pay­load bet­ter than an­ti­bod­ies, has bro­ken out the terms of its IPO. The Cam­bridge, Unit­ed King­dom-based com­pa­ny plans to of­fer 4.3 mil­lion Amer­i­can De­posi­tary Shares (ADSs) in the price range of $14 to $16 to raise $65 mil­lion, it said in a fil­ing on Mon­day. Bi­cy­cle, which was found­ed in 2009 and has raised $147 mil­lion in cash al­ready, plans to list un­der the sym­bol BCYC.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.